Acrux Ltd
Company Profile
Business description
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.
Contact
103-113 Stanley Street
West Melbourne
MelbourneVIC3003
AUST: +61 383790100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
36
Stocks News & Analysis
stocks
The ‘other’ AI chip behemoth that might just be getting started
stocks
Why ANZ changes aren’t just about cutting costs
stocks
Strong finish to the year for overvalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,095.20 | 28.80 | 0.32% |
CAC 40 | 7,772.88 | 23.49 | 0.30% |
DAX 40 | 23,775.52 | 57.07 | 0.24% |
Dow JONES (US) | 45,711.34 | 196.39 | 0.43% |
FTSE 100 | 9,261.54 | 19.01 | 0.21% |
HKSE | 26,200.26 | 262.13 | 1.01% |
NASDAQ | 21,879.49 | 80.79 | 0.37% |
Nikkei 225 | 43,837.67 | 378.38 | 0.87% |
NZX 50 Index | 13,276.24 | 22.51 | 0.17% |
S&P 500 | 6,512.61 | 17.46 | 0.27% |
S&P/ASX 200 | 8,830.40 | 40.00 | 0.46% |
SSE Composite Index | 3,812.22 | 4.93 | 0.13% |